Results 31 to 40 of about 3,492,883 (216)

Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer.

Int J Oncol, 2018
Currently, resistance to tyrosine kinase inhibitors, such as erlotinib, has become a major obstacle for improving the clinical outcome of patients with metastatic and advanced-stage non-small cell lung cancer (NSCLC). While cell behavior can be modulated
Zhang W, Cai X, Yu J, Lu X, Qian Q, Qian W.   +5 more
europepmc   +2 more sources

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. [PDF]

PLoS Medicine, 2005
Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR)
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus   +7 more
doaj   +2 more sources

Multi-omics analysis reveals that ornithine decarboxylase contributes to erlotinib resistance in pancreatic cancer cells. [PDF]

Oncotarget, 2017
Molecular and metabolic alterations in cancer cells are one of the leading causes of acquired resistance to chemotherapeutics. In this study, we explored an experimental strategy to identify which of these alterations can induce erlotinib resistance in ...
Jang WJ, Choi B, Song SH, Lee N, Kim DJ, Lee S, Jeong CH.   +6 more
europepmc   +2 more sources

YAP promotes erlotinib resistance in human non-small cell lung cancer cells [PDF]

Oncotarget, 2016
Yes-associated protein (YAP) is a main mediator of the Hippo pathway, which promotes cancer development. Here we show that YAP promotes resistance to erlotinib in human non-small cell lung cancer (NSCLC) cells.
Ping-Chih Hsu, Bin You, Yi-lin Yang, Wenqian Zhang, Yu-cheng Wang, Zhidong Xu, Yuyuan Dai, Shu Liu, Cheng-Ta Yang, Hui Li, Bin Hu, D. Jablons, L. You   +12 more
semanticscholar   +5 more sources

Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non–small-cell lung cancer

Tumor Biology, 2017
Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors, such as gefitinib and erlotinib, is a critical issue in the treatment of patients with epidermal growth factor receptor mutant–positive non–small-cell lung cancer. Recent
Huake Sun, Huiwen Ma, Jianmin Wang, Liqin Xia, Guangkuo Zhu, Zhoufei Wang, Jianguo Sun, Zhengtang Chen   +7 more
doaj   +2 more sources

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

Cells, 2021
Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs).
Nadiia Lypova, Susan M. Dougherty, Lilibeth Lanceta, Jason Chesney, Yoannis Imbert-Fernandez   +4 more
doaj   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives [PDF]

Frontiers in Pharmacology, 2013
Lung cancer is the most common cancer in the world. Despite modern advancements in surgeries, chemotherapies, and radiotherapies over the past few years, lung cancer still remains a very difficult disease to treat. This has left the death rate from lung cancer victims largely unchanged throughout the past few decades. A key cause for the high mortality
Tang, Joy, Salama, Rasha, Gadgeel, Shirish M., Sarkar, Fazlul H., Ahmad, Aamir   +4 more
openaire   +3 more sources

Reversion of erlotinib-acquired resistance twice by chemotherapy [PDF]

Cancer Biology & Therapy, 2013
Epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC) usually develop disease progression after a median of 10 to 14 mo on tyrosine kinase inhibitor (TKI). Several mechanisms of resistance to TKI have been described, threonine-methionine substitution at position 790 (T790M), mesenchymal-epithelial ...
Fei-fei, Teng, Jian-dong, Zhang, Xue, Meng, Jin-ming, Yu   +3 more
openaire   +2 more sources

Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines

Biomedicines, 2023
Resistance to protein tyrosine kinase inhibitors (TKIs) presents a significant challenge in therapeutic target development for cancers such as triple-negative breast cancer (TNBC), where conventional therapies are ineffective at combatting systemic ...
Cory Lefebvre, Sierra Pellizzari, Vasudeva Bhat, Kristina Jurcic, David W. Litchfield, Alison L. Allan   +5 more
doaj   +1 more source